M Pharmaceutical Launches New Corporate Identity

M Pharmaceutical Inc. (CSE:MQ,OTCQB:MPHMF) launched a new corporate identity to better communicate biomedical technologies designed to improve the health of those affected by obesity and diabetes. Joining the eMosquito Wearable Blood Monitor will be Trimeo Weight Loss Capsules and the Trimtec Gastric Stimulation System.
As quoted in the press release:

M Pharmaceutical, Inc. is using the new corporate identity to reinforce its commitment to developing and commercializing its innovative biomedical technologies which offer the end user realistic solutions based on the principles of reduced invasiveness and enhanced effectiveness.
The mantra “Better Health. Better Life.” will be prominent in the rebranding, as will the connectivity and synergies between the eMosquito Wearable Blood Monitor, Trimeo Weight Loss Capsules and Trimtec Gastric Stimulation System.
The family of biomedical products are linked by the common “M” embedded in a stylized Circle of Life. The corporate brand mark and all product marks will share the common M in a colour-coded protocol that will be consistently applied across all communications platforms.
“The Circle of Life that will represent M Pharmaceutical, Inc. going forward is designed to remind all of us and our stakeholders of the importance of collaboration in the execution of our
business plan and invoke the targeted focus we have around providing integrated solutions for the people who need our biomedical technologies most,” added Dr. Mintchev.
“We commissioned the rebranding because we felt it was the best way to bring our family of biomedical technologies together under one roof,” said George Tsafalas, a member of the Board of Directors of M Pharmaceutical, Inc. “Based on the quality of people who have joined with Dr. Mintchev on our leadership team, our Board and our Advisory group, and given the progress the team has made on all fronts, we believed it was the right time to usher in our new look and feel.”

M Pharmaceutical President & CEO, Dr. Martin Mintchev, said:

Our new approach and communications platform will help us in our pursuit of excellence in the biomedical technologies that we believe will make a palpable difference in the lives of people living with obesity and diabetes. The rebranding simplifies the comprehensive vision of M Pharmaceutical, Inc. and crystalizes the story behind the eMosquito. In introducing Trimeo and Trimtec to our family, it represents an exciting new chapter in the growth and development of our company.

Click here for the full M Pharmaceutical Inc (CSE:MQ,OTCQB:MPHMF) press release.
Click here for the M Pharmaceutical Inc (CSE:MQ,OTCQB:MPHMF) profile.